Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.